Shares of Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) dropped 7.8% during mid-day trading on Friday . The stock traded as low as $12.31 and last traded at $12.35. Approximately 577,515 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 2,138,228 shares. The stock had previously closed at $13.39.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the company. HC Wainwright restated a "buy" rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 8th. The Goldman Sachs Group cut their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th.
Read Our Latest Analysis on Dynavax Technologies
Dynavax Technologies Stock Down 8.4 %
The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 95.16 and a beta of 1.34. The firm has a 50 day moving average of $11.32 and a two-hundred day moving average of $11.29.
Institutional Trading of Dynavax Technologies
A number of hedge funds have recently added to or reduced their stakes in the stock. HighVista Strategies LLC boosted its holdings in shares of Dynavax Technologies by 4.2% during the 3rd quarter. HighVista Strategies LLC now owns 162,708 shares of the biopharmaceutical company's stock valued at $1,813,000 after acquiring an additional 6,547 shares in the last quarter. Centiva Capital LP acquired a new stake in shares of Dynavax Technologies during the third quarter valued at about $119,000. Paloma Partners Management Co bought a new stake in shares of Dynavax Technologies during the third quarter worth about $280,000. PDT Partners LLC acquired a new position in shares of Dynavax Technologies in the third quarter valued at approximately $3,967,000. Finally, Bank of Montreal Can raised its holdings in Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock valued at $11,848,000 after buying an additional 82,449 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.
Dynavax Technologies Company Profile
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
